InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.845 -0.005 (-0.59%)+
Announcement
Release
28 Apr 2026 9:10AM
Price at Release
$0.850
Full Release
download
Summary
Orthocell Limited announced that their product, Remplir™, achieved a 90% success rate in a real-world study involving 66 patients with peripheral nerve conditions. The study, which indicated no complications, reinforces Remplir's position as a leading nerve repair treatment in Australia and supports its ongoing commercial expansion in the U.S. and Europe. The high success rates across various nerve repair procedures demonstrate its effectiveness and safety, contributing to its increasing adoption among surgeons globally. Regulatory approval for Remplir in new markets is anticipated by the second half of 2026.
Key Points
  • Remplir™ demonstrates an overall treatment success rate of 89.7%.
  • The study involved 66 patients aged 14 to 82 years.
  • Majority of procedures were performed in the upper limb.
  • No post-treatment complications reported, indicating high safety and biocompatibility.
  • 90.3% of motor nerve repairs resulted in functional muscle recovery.
  • 89.4% of nerve decompression procedures showed significant symptom improvement.
  • The study supports commercial growth in the U.S. and upcoming European markets.
  • Orthocell is focused on expanding Remplir's adoption globally.
  • Regulatory approval expected in H2 CY26.
  • More than 300 surgeons in Australia and 49 in the U.S. are using Remplir.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.